Candidiasis – Pipeline Review, 2019

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1. Introduction

1.1.Report Overview

2. Candidiasis - Overview

3. Executive Summary

4. Candidiasis : Pipeline Assessment

4.1. ByStage of Development

4.2. ByRoute of Administration

4.3. ByDrug Class

4.4. ByMolecule Type

4.5. ByTherapy Area / Indication

4.6. ByDrug Target

4.7. BySponsor

5. Candidiasis: Company & Drug Profiles

5.1.Clinical Stage

5.1.1. NDV-3A – NovaDigm Therapeutics, Inc.

5.1.1.1. Company Overview

5.1.1.2. Product Description

5.1.1.3. R&D Status & DevelopmentActivities

5.1.1.4. Mechanism of Action

5.1.1.5. Molecule Type

5.1.1.6. Stage of Development

5.1.1.7. Indications

5.1.1.8. Route of Administration

5.1.1.9. Funding

5.1.2. PAC113 – Pacgen Life ScienceCorporation

5.1.2.1. Company Overview

5.1.2.2. Product Description

5.1.2.3. R&D Status & DevelopmentActivities

5.1.2.4. Mechanism of Action

5.1.2.5. Molecule Type

5.1.2.6. Stage of Development

5.1.2.7. Indications

5.1.2.8. Route of Administration

5.1.2.9. Funding

5.1.3. FK463 – Astellas Pharma Inc.

5.1.3.1. Company Overview

5.1.3.2. Product Description

5.1.3.3. R&D Status & DevelopmentActivities

5.1.3.4. Mechanism of Action

5.1.3.5. Molecule Type

5.1.3.6. Stage of Development

5.1.3.7. Indications

5.1.3.8. Route of Administration

5.1.3.9. Funding

5.1.4. Others

5.2.Preclinical

5.2.1. Company Overview

5.2.2. Product Description

5.2.3. R&D Status & DevelopmentActivities

5.2.4. Mechanism of Action

5.2.5. Molecule Type

5.2.6. Indications

5.2.7. Route of Administration

5.2.8. Funding

6. Candidiasis: An Overview on Dormant & DiscontinuedPipeline Candidates

6.1.Overview

6.2.Product Description

6.3.Reason for Discontinuation

7. Candidiasis: Additional Key Insights

7.1.Epidemiology Overview: Candidiasis

7.2.Current Market Scenario: Candidiasis Therapeutics

8. Candidiasis: News, Press Releases and ConferenceDetails 

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.